These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32501541)

  • 1. Pharmacokinetics, safety and tolerability of long-acting parenteral intramuscular injection formulations of doravirine.
    Yee KL; Mittal S; Fan L; Triantafyllou I; Dockendorf MF; Fackler PH; Stoch SA; Khalilieh SG; Iwamoto M
    J Clin Pharm Ther; 2020 Oct; 45(5):1098-1105. PubMed ID: 32501541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine.
    Boyle A; Moss CE; Marzolini C; Khoo S
    Clin Pharmacokinet; 2019 Dec; 58(12):1553-1565. PubMed ID: 31388941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.
    Anderson MS; Khalilieh S; Yee KL; Liu R; Fan L; Rizk ML; Shah V; Hussaini A; Song I; Ross LL; Butterton JR
    Clin Pharmacokinet; 2017 Jun; 56(6):661-669. PubMed ID: 27699622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV.
    Matthews RP; Jackson Rudd D; Fillgrove KL; Zhang S; Tomek C; Stoch SA; Iwamoto M
    Clin Drug Investig; 2021 Jul; 41(7):629-638. PubMed ID: 34151413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.
    Yee KL; Khalilieh SG; Sanchez RI; Liu R; Anderson MS; Manthos H; Judge T; Brejda J; Butterton JR
    Clin Drug Investig; 2017 Jul; 37(7):659-667. PubMed ID: 28353169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers.
    Khalilieh SG; Yee KL; Fan L; Liu R; Heber W; Dunzo E; Triantafyllou I; Hussaini A; Iwamoto M
    Clin Drug Investig; 2017 Oct; 37(10):975-984. PubMed ID: 28785879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate.
    Yee KL; DiBenedetto A; Fan L; Khalilieh S; Triantafyllou I; Vallee MH; Fackler P; Stoch SA; Iwamoto M
    AAPS PharmSciTech; 2020 Feb; 21(3):91. PubMed ID: 32060665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
    Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
    Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
    Landovitz RJ; Li S; Grinsztejn B; Dawood H; Liu AY; Magnus M; Hosseinipour MC; Panchia R; Cottle L; Chau G; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; Zhang Y; Tolley E; Sugarman J; Kofron R; Adeyeye A; Burns D; Rinehart AR; Margolis D; Spreen WR; Cohen MS; McCauley M; Eron JJ
    PLoS Med; 2018 Nov; 15(11):e1002690. PubMed ID: 30408115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone.
    Khalilieh S; Yee KL; Sanchez RI; Vaynshteyn K; Fan L; Searle S; Bouhajib M; Iwamoto M
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):151-161. PubMed ID: 31120195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
    Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Rodgers A; Lupinacci L; Kumar S; Sklar P; Hanna GJ; Hwang C; Martin EA;
    Lancet HIV; 2020 Jan; 7(1):e16-e26. PubMed ID: 31740348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions.
    Khalilieh S; Yee KL; Sanchez R; Stoch SA; Wenning L; Iwamoto M
    Clin Drug Investig; 2020 Oct; 40(10):927-946. PubMed ID: 32816220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals.
    Schürmann D; Sobotha C; Gilmartin J; Robberechts M; De Lepeleire I; Yee KL; Guo Y; Liu R; Wagner F; Wagner JA; Butterton JR; Anderson MS
    AIDS; 2016 Jan; 30(1):57-63. PubMed ID: 26372481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects.
    Yee KL; Sanchez RI; Auger P; Liu R; Fan L; Triantafyllou I; Lai MT; Di Spirito M; Iwamoto M; Khalilieh SG
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics.
    Khalilieh S; Yee KL; Liu R; Fan L; Sanchez RI; Auger P; Triantafyllou I; Stypinski D; Lasseter KC; Marbury T; Iwamoto M
    J Clin Pharmacol; 2017 Jun; 57(6):777-783. PubMed ID: 28026013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults.
    Spreen W; Williams P; Margolis D; Ford SL; Crauwels H; Lou Y; Gould E; Stevens M; Piscitelli S
    J Acquir Immune Defic Syndr; 2014 Dec; 67(5):487-92. PubMed ID: 25473882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Study to Evaluate Doravirine Pharmacokinetics When Coadministered With Acid-Reducing Agents.
    Khalilieh SG; Yee KL; Sanchez RI; Fan L; Vaynshteyn K; Deschamps K; Martell M; Jordan HR; Iwamoto M
    J Clin Pharmacol; 2019 Aug; 59(8):1093-1098. PubMed ID: 30817001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
    Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Xu X; Rodgers A; Lupinacci L; Kumar S; Sklar P; Nguyen BY; Hanna GJ; Hwang C;
    Lancet HIV; 2018 May; 5(5):e211-e220. PubMed ID: 29592840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of gender and age on the relative bioavailability of doravirine: results of a Phase I trial in healthy subjects.
    Behm MO; Yee KL; Fan L; Fackler P
    Antivir Ther; 2017; 22(4):337-344. PubMed ID: 28206979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Food on Doravirine Bioavailability: Results from Two Pharmacokinetic Studies in Healthy Subjects.
    Behm MO; Yee KL; Liu R; Levine V; Panebianco D; Fackler P
    Clin Drug Investig; 2017 Jun; 37(6):571-579. PubMed ID: 28349328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.